Want to see NUVB full AI Analyst Report?
NUVB Stock Chart & Stats
$7.10
-$0.07(-1.08%)
At close: 4:00 PM EDT
$7.10
-$0.07(-1.08%)
Day’s Range― - ―
52-Week Range$2.99 - $9.75
Previous CloseN/A
Volume6.14M
Average Volume (3M)5.67M
Market Cap
$2.34B
Enterprise Value$1.74K
Total Cash (Recent Filing)$660.96M
Total Debt (Recent Filing)$252.14M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Nov 11, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding351,123,230
10 Day Avg. Volume5,088,005
30 Day Avg. Volume5,667,301
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)10.01
Price to Sales (P/S)48.65
P/FCF Ratio-17.61
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.50Price Target Upside104.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.39
Revenue Forecast (FY)$200.50M
Bulls Say, Bears Say
Bulls Say
IBTROZI Growth And Market LeadershipStrong quarterly growth and first-line leadership support durable revenue expansion as treatment shifts toward longer-duration use. The growing ROS1 market and increasing first-line starts can broaden the treated patient base and strengthen commercial scale.
Differentiated Clinical ProfileHigh response rates, durable disease control and favorable tolerability can support physician adoption and patient retention. Its brain penetration without CNS label warnings provides a potential differentiation that may remain relevant against competing ROS1 therapies.
Strong Liquidity And Low LeverageThe substantial cash balance and modest leverage provide funding flexibility for commercialization and clinical development. Long-dated, low-coupon financing and retirement of the secured loan may reduce near-term interest pressure and extend operational runway.
Bears Say
Persistent Losses And Cash BurnThe company remains materially unprofitable and consumes cash despite revenue growth. Continued clinical and commercial investment could require additional financing before sustainable cash generation, creating ongoing funding dependence and potential shareholder dilution.
High Operating Costs And Gross-to-net PressureHeavy commercialization and development spending limits operating leverage while payer deductions reduce realized product revenue. If expenses remain elevated and deductions do not improve, revenue growth may take longer to translate into breakeven or durable profitability.
Long And Uncertain Clinical MilestonesKey pipeline value depends on multi-year trials and regulatory outcomes, delaying potential approvals and incremental revenue. Reliance on exploratory endpoints or small cohorts adds execution and approval risk beyond the established IBTROZI commercial business.
Nuvation Bio News
NUVB FAQ
What was Nuvation Bio’s price range in the past 12 months?
Nuvation Bio lowest stock price was $2.99 and its highest was $9.75 in the past 12 months.
What is Nuvation Bio’s market cap?
Nuvation Bio’s market cap is $2.34B.
When is Nuvation Bio’s upcoming earnings report date?
Nuvation Bio’s upcoming earnings report date is Nov 11, 2026 which is in 69 days.
How were Nuvation Bio’s earnings last quarter?
Nuvation Bio released its earnings results on Aug 06, 2026. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.038.
Is Nuvation Bio overvalued?
According to Wall Street analysts Nuvation Bio’s price is currently Undervalued.
Does Nuvation Bio pay dividends?
Nuvation Bio does not currently pay dividends.
What is Nuvation Bio’s EPS estimate?
Nuvation Bio’s EPS estimate is -0.12.
How many shares outstanding does Nuvation Bio have?
Nuvation Bio has 351,123,230 shares outstanding.
What happened to Nuvation Bio’s price movement after its last earnings report?
Nuvation Bio reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went down -4.082%.
Which hedge fund is a major shareholder of Nuvation Bio?
Currently, no hedge funds are holding shares in NUVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvation Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.50 (104.23% Upside)
$14.50 (104.23% Upside)
Blogger Sentiment
Bullish
NUVB Sentiment 87%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 138.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $118.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 6.1%
Last 30 Days ▲ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.03%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Nuvation Bio
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
NUVB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive commercial and clinical trajectory: IBTROZI is demonstrating strong revenue growth, clear market leadership in first-line ROS1, exceptional clinical durability and favorable patient-reported outcomes, while safusidenib shows encouraging long-term activity and an expanded development plan. The company further strengthened its balance sheet via a well‑subscribed convertible note offering. Key near-term challenges include elevated operating expenses, gross-to-net pressure, community testing and prescribing inertia, and multi‑year timelines for Phase III readouts. Competitive entrants and dilution risk exist but were framed as manageable. On balance, the highlights (robust revenue growth, market share leadership, best-in-class clinical data, strong cash position and program expansion) materially outweigh the lowlights.View all NUVB earnings summariesNUVB Stock 12 Month Forecast
Average Price Target
$14.50
▲(104.23% Upside)
Technical Analysis
Nektar Therapeutics
―
Precigen
―
Wave Life Sciences
―
Enliven Therapeutics
―
Praxis Precision Medicines
―
Ownership Overview
24.64% Insiders
15.63% Mutual Funds
19.72% Other Institutional Investors
28.73% Public Companies and Individual Investors